Late-onset Pompe's disease

Seminars in Neurology

Volumn 32, Issue 5, 2012, Pages 506-511

  Teener, James W ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

acid maltase deficiency; glycogen storage disease type II; lysosomal storage disease; Pompe's disease

Indexed keywords

CREATINE KINASE; GLUCAN 1,4 ALPHA GLUCOSIDASE; GLYCOGEN; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE;

ABDUCTION; ADULT; ARTICLE; CASE REPORT; CLIMBING; DELTOID MUSCLE; DYSPNEA; ENZYME ACTIVITY; ENZYME REPLACEMENT; GLUTEUS MAXIMUS MUSCLE; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; ILIOPSOAS MUSCLE; LABORATORY TEST; LUNG FUNCTION TEST; MALE; MUSCLE WEAKNESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; VASTUS LATERALIS MUSCLE;

AGE OF ONSET; ALPHA-GLUCOSIDASES; DISEASE PROGRESSION; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; TREATMENT OUTCOME;

EID: 84878095510     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0033-1334469     Document Type: Article

References (33)

1. Chien Y. H., Chiang S. C., Zhang X. K., et al. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics: 2008; 122 1 e39 e45
2. Ausems M. G., Verbiest J., Hermans M. P., et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet: 1999; 7 6 713 716
3. Ausems M. G., Lochman P., van Diggelen O. P., Ploos van Amstel H. K., Reuser A. J., Wokke J. H. A diagnostic protocol for adult-onset glycogen storage disease type II. Neurology: 1999; 52 4 851 853
4. Martiniuk F., Chen A., Mack A., et al. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet: 1998; 79 1 69 72
5. Raben N., Takikita S., Pittis M. G., et al. Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand.. Autophagy: 2007; 3 6 546 552
6. Winkel L. P., Hagemans M. L., van Doorn P. A., et al. The natural course of non-classic Pompe's disease; a review of 225 published cases. J Neurol: 2005; 252 8 875 884
7. Hagemans M. L., Winkel L. P., Van Doorn P. A., et al. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain: 2005; 128 Pt 3 671 677
8. Yanovitch T. L., Casey R., Banugaria S. G., Kishnani P. S. Improvement of bilateral ptosis on higher dose enzyme replacement therapy in Pompe disease. J Neuroophthalmol: 2010; 30 2 165 166
9. Sacconi S., Bocquet J. D., Chanalet S., Tanant V., Salviati L., Desnuelle C. Abnormalities of cerebral arteries are frequent in patients with late-onset Pompe disease. J Neurol: 2010; 257 10 1730 1733
10. Barohn R. J., McVey A. L., DiMauro S. Adult acid maltase deficiency. Muscle Nerve: 1993; 16 6 672 676
11. van der Ploeg A. T. Monitoring of pulmonary function in Pompe disease: a muscle disease with new therapeutic perspectives. Eur Respir J: 2005; 26 6 984 985
12. Berger K. I., Skrinar A., Norman R. G., et al. Ventilatory dysfunction in late-onset Pompe disease. Proc Am Thorac Soc: 2005; 171 A788
13. Schoser B. G., Müller-Höcker J., Horvath R., et al. Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited. Neuropathol Appl Neurobiol: 2007; 33 5 544 559
14. Kishnani P. S., Steiner R. D., Bali D., et al. Pompe disease diagnosis and management guideline. Genet Med: 2006; 8 5 267 288
15. Pichiecchio A., Uggetti C., Ravaglia S., et al. Muscle MRI in adult-onset acid maltase deficiency. Neuromuscul Disord: 2004; 14 1 51 55
16. Kallwass H., Carr C., Gerrein J., et al. Rapid diagnosis of late-onset Pompe disease by fluorometric assay of alpha-glucosidase activities in dried blood spots. Mol Genet Metab: 2007; 90 4 449 452
17. Mutations in human acid alpha-glucosidase. Pompe Center. Available at: www.pompe.com/en/healthcare-professionals/genetics-epidemiology/mutations.aspx. Accessed February 1, 2013
18. Van den Hout J. M., Reuser A. J., de Klerk J. B., Arts W. F., Smeitink J. A., Van der Ploeg A. T. Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis: 2001; 24 2 266 274
19. Kishnani P. S., Corzo D., Nicolino M., et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology: 2007; 68 2 99 109
20. Amalfitano A., Bengur A. R., Morse R. P., et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med: 2001; 3 2 132 138
21. Van den Hout J. M., Kamphoven J. H., Winkel L. P., et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics: 2004; 113 5 e448 e457
22. Winkel L. P., Van den Hout J. M., Kamphoven J. H., et al. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann Neurol: 2004; 55 4 495 502
23. van der Ploeg A. T., Clemens P. R., Corzo D., et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med: 2010; 362 15 1396 1406
24. Cupler E. J., Berger K. I., Leshner R. T., et al. AANEM Consensus Committee on Late-onset Pompe Disease Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve: 2012; 45 3 319 333
25. Genzyme Corporation Lumizyme ACE Program. Available at: http://www.lumizyme.com/healthcare/lumizyme-ace-program.aspx. Accessed May 2, 2012
26. Mellies U., Ragette R., Schwake C., Baethmann M., Voit T., Teschler H. Sleep-disordered breathing and respiratory failure in acid maltase deficiency. Neurology: 2001; 57 7 1290 1295
27. Mellies U., Stehling F., Dohna-Schwake C., Ragette R., Teschler H., Voit T. Respiratory failure in Pompe disease: treatment with noninvasive ventilation. Neurology: 2005; 64 8 1465 1467
28. Laforêt P., Doppler V., Caillaud C., et al. Rigid spine syndrome revealing late-onset Pompe disease. Neuromuscul Disord: 2010; 20 2 128 130
29. Brooke M. H., Fenichel G. M., Griggs R. C., et al. Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology: 1989; 39 4 475 481
30. Granata C., Merlini L., Cervellati S., et al. Long-term results of spine surgery in Duchenne muscular dystrophy. Neuromuscul Disord: 1996; 6 1 61 68
31. van den Berg L. E., Zandbergen A. A., van Capelle C. I., et al. Low bone mass in Pompe disease: muscular strength as a predictor of bone mineral density. Bone: 2010; 47 3 643 649
32. Schoser B., Hill V., Raben N. Therapeutic approaches in glycogen storage disease type II/Pompe Disease. Neurotherapeutics: 2008; 5 4 569 578
33. Bernstein D. L., Bialer M. G., Mehta L., Desnick R. J. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients. Mol Genet Metab: 2010; 101 2-3 130 133